Institute stops trial on Revatio for sickle cell disease

07/29/2009 | Wall Street Journal, The

The National Heart, Lung and Blood Institute halted a study on Revatio, a drug that contains the key ingredient in Viagra, in patients with sickle cell disease because of safety issues. The study indicated a significantly higher risk of serious side effects in patients taking Revatio compared with those on placebo.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Corporate Counsel - Regulatory Law
Regeneron
Tarrytown, NY
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Active Implantable Medical Device (AIMD) Product Expert
BSI
Nationwide, SL_Nationwide
Finance Manager - ENT
Medtronic
Jacksonville, FL
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA